A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777
This study is recruiting at 11 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease. Study periods for the intervention-specific appendix (ISA) will be as follows: A 12-week induction period A maintenance period from Week 12 to Week 52, and A safety follow-up period up to 16 weeks. The study will last about 74 weeks and may include up to 19 visits.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Crohn's Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 2 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Eli Lilly and Company
- Last updated on ClinicalTrials.gov
- October 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Connecticut Children's Medical Center · Hartford, CT
Georgia · 2
- Children's Center for Digestive Health Care, LLC · Atlanta, GA
- Emory University · Atlanta, GA
Indiana · 1
- Riley Childrens Hospital · Indianapolis, IN
New York · 3
- Columbia University Medical Center/New York Presbyterian · New York, NY
- Icahn School of Medicine at Mount Sinai · New York, NY
- Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC) · New York, NY
Ohio · 1
- Childrens Medical Center · Dayton, OH
Pennsylvania · 1
- Children's Hospital of Philadelphia · Philadelphia, PA
Texas · 1
- Cook Children's Medical Center · Fort Worth, TX
Vermont · 1
- University of Vermont Medical Center · Burlington, VT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.